Current market sentiment around Takeda stock price forecast is buoyed by its recent R&D pipeline updates. Forecast models predict a 5–7% upside in the next six months, driven by solid revenues and stable currency conditions in yen. Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), emphasized increased funding in cell and gene therapies in 2024 in his opening remarks at the October 7 conference. Thirteen of the fifteen biggest pharmaceutical companies in the world by market capitalization, he said, now have an "active presence" in this area. Major pharmaceutical corporations are increasingly turning to cell and gene therapies to fill possible revenue shortages as many product patents are about to expire. Despite this enthusiasm, there has been a reduction in related patent filings, and the number of cell and gene therapy deals in the pharmaceutical industry fell by 38% in Q2 2024 compared to the same time in 2023. Nevertheless, the sector is appealing and should not be disregarded by investors. Overall TAK ranks 6th on our list of the best Japanese stocks to buy. While we acknowledge the potential of TAK as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TAK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . Takeda stock price forecast points towards a consolidation phase around ¥4,200 before a potential breakout. Technical charts show 50-day moving average crossing above the 200-day MA, a common bullish signal for pharma equities.
